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CASE REPORT
Relapse of both small cell lung cancer 
and Lambert–Eaton myasthenic syndrome 
after a 13-year disease-free survival period
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Abstract 
Lambert–Eaton myasthenic syndrome (LEMS) is a paraneoplastic syndrome and only 3% of small cell lung carcinoma 
(SCLC) patients have LEMS. Moreover, the recurrence of SCLC after a disease-free survival (DFS) of more than 10 years 
is rare. We report a patient who had a recurrence of both SCLC and LEMS after a 13-year DFS period. A 69-year-old 
man was diagnosed with LEMS and SCLC (cT0N2M0, stage IIIA) 13 years ago. Chemoradiotherapy was performed 
and a complete response was achieved. With anticancer treatment, the LEMS symptoms was alleviated. At the age 
of 82 years, gait disturbance appeared followed by left supraclavicular lymphadenopathy and further examination 
revealed the recurrence of SCLC. Careful screening for the recurrence of SCLC might be needed when the patient has 
recurrent or secondary paraneoplastic neurological syndrome even after a long DFS period.
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Background
Lambert–Eaton myasthenic syndrome (LEMS) is a para-
neoplastic syndrome and only 3% of small cell lung car-
cinoma (SCLC) patients have LEMS [1]. In addition, 
SCLC recurrence after a disease-free survival (DFS) of 
more than 10  years is rare [2–4]. Herein, we report a 
patient with a recurrence of both SCLC and LEMS after a 
13-year DFS period. Our case might indicate the impor-
tance of SCLC recurrence screening in patients with a 
recurrence or a secondary paraneoplastic neurological 
syndrome (PNS) even after a long DFS period.
Case presentation
In December 2001, a 69-year-old man was referred 
to our hospital for gait disturbance and dysarthria. 
Chest computed tomography (CT) showed mediasti-
nal lymphadenopathy (Fig.  1a) and the accumulation of 
2-deoxy-2-[18F]fluoro-d-glucose (FDG) was detected by 
positron emission tomography (PET). The serum level 
of pro-gastrin-releasing peptide was 38.3  pg/mL. The 
specimen obtained by lymph node biopsy with medias-
tinoscopy revealed small cell carcinoma (Fig.  2) and he 
was diagnosed with SCLC (cT0N2M0, stage IIIA). The 
serum level of P/Q-type anti-voltage-gated calcium chan-
nel (VGCC) antibody was extremely high (1476 pmol/L; 
upper limit of normal, 20 pmol/L) and electromyography 
(EMG) showed waxing at 50 Hz (Fig. 1b). Therefore, the 
diagnosis of LEMS with SCLC was made. Plasmapher-
esis, intravenous immunoglobulin and 3,4-diaminopyri-
dine therapy were performed, but the symptoms did not 
improve and the serum level of P/Q-type VGCC anti-
body remained high (1608 pmol/L).
Carboplatin (area under the curve: 5  mg/mL, day 1) 
and etoposide (100 mg/m2, days 1–3) were intravenously 
administered every 4 weeks (total eight cycles) and radi-
otherapy of the mediastinum with a total dose of 45 Gy 
(1.5  Gy/fraction, twice daily) was delivered. A complete 
response was achieved. The serum level of P/Q-type 
VGCC antibody had remarkably decreased to 958 pmol/L 
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after the first three chemotherapy cycles; after all eight 
cycles, it decreased from 1608 to 40  pmol/L. Gait dis-
turbance and dysarthria were alleviated. SCLC had not 
recurred for 13 years.
In January 2015, at the age of 82  years, the patient 
developed gait disturbance followed by left supraclavicu-
lar lymphadenopathy. Further examination of left supra-
clavicular lymphadenopathy was performed. Physical 
Fig. 1 Radiological findings and electromyography on a small cell lung carcinoma (SCLC) patient with Lambert–Eaton myasthenic syndrome 
(LEMS). a Chest computed tomography (CT) revealed mediastinal lymphadenopathy (arrow) on February 7, 2002. b Electromyography following 
stimulation at 50 Hz showed waxing on March 13, 2002
Fig. 2 Pathological and cytological findings in an SCLC patient with LEMS. Specimens were obtained by cervical lymph node biopsy on February 
14, 2002. Paraffin-embedded sections were stained with antibody using the polymer method (The Dako Envision™ FLEX, Dako Japan, Tokyo, Japan) 
and signal was developed with diaminobenzidine (DAB). Sections were counterstained with hematoxylin. Positive staining for markers in cytoplasm 
and on cell membrane was indicated in brown. a There are dense sheets of small cells with nuclear molding and necrosis (hematoxylin–eosin stain-
ing). b CD56 was diffusely and strongly positive on cell membrane. c Chromogranin A was diffusely and moderately expressed in cytoplasm.  
d Synaptophysin was focally and weakly expressed in cytoplasm
Page 3 of 5Asano et al. Chin J Cancer  (2016) 35:63 
examination revealed proximal muscle weakness and 
reduced tendon reflexes in the lower extremities. His 
chest radiography showed a 3.5 × 2.5 cm nodule on the 
aortic arch of the left upper lung lobe and a 4.4 × 2.3 cm 
nodule on the pulmonary hilar of the left middle lung 
lobe. Chest contrast CT revealed supraclavicular, medi-
astinal and pulmonary hilar lymphadenopathy (Fig.  3a) 
and FDG PET-CT showed FDG accumulation (Fig.  3b). 
The serum level of pro-gastrin-releasing peptide was 
442.3  pg/mL. Cervical lymph node needle aspiration 
biopsy revealed small cell carcinoma in the supraclavic-
ular lymph node (Fig.  4) and the patient was diagnosed 
with SCLC recurrence. The serum level of P/Q-type 
VGCC antibody was 172.6  pmol/L and EMG showed 
waxing at 20  Hz (Fig.  3c). Therefore, he had recurrence 
of both SCLC and LEMS. Carboplatin (area under the 
curve: 5 mg/mL, day 1) and etoposide (100 mg/m2, days 
1–3) were intravenously administered every 4  weeks (a 
total of six cycles and the dose was reduced to 80% from 
the fourth cycle because of grade 4 neutropenia). Chem-
otherapy achieved a partial response and alleviation of 
his symptoms.
Discussion
When lung cancer is diagnosed after a long DFS period, 
it is difficult to decide whether it is due to a recurrence 
or a secondary primary lung cancer. A 5-year DFS is 
an indicator of the cure of SCLC [5]. However, in some 
cases of SCLC, a recurrence after a DFS period of more 
than 10  years has been reported [2–4]. We consid-
ered the present case as a recurrence of SCLC for a few 
reasons. First, the immunological staining pattern of 
specimens obtained in 2015 was similar to that in 2001, 
although synaptophysin expression was not observed in 
2015. Second, recurrence is more common than a sec-
ond primary SCLC in SCLC patients with a long survival 
period. In 60 patients with SCLC who survived for more 
than 5 years, nine had SCLC recurrence and none had a 
second primary SCLC [6]. Johnson et  al. [7] studied 62 
SCLC patients with a DFS period of more than 2  years 
and reported that 18 had recurrence whereas two had 
a second primary SCLC. Third, considering the dou-
bling time, a recurrence after a DFS period of more than 
13  years is quite possible [2]. Moreover, in our case, 
SCLC reappeared on the same side of the mediastinal 
lymph nodes. Therefore, we considered this case as a 
recurrence of SCLC. A small amount of SCLC cells had 
grown for 13 years. However, there remains the possibil-
ity of recurrence.
In the study of secondary PNS by Ducray et  al. [8], it 
was reported that, in all patients with a cancer recur-
rence, a secondary PNS antedated the cancer recur-
rence. In our case, gait disturbance was presented before 
the diagnosis of an SCLC recurrence. If the patient has 
a recurrence or a secondary PNS, careful screening for 
cancer recurrence is needed.
The etiology of PNS recurrence might be mediated by 
onconeural antibody production stimulated by the recur-
rence of SCLC. In this case, the serum level of P/Q-type 
VGCC antibody was elevated with the recurrence of 
SCLC and LEMS. A previous study reported that, among 
the patients with PNS positive for onconeural antibody, 
the same antibody was detected when a secondary PNS 
appeared [8]. Nagashima et  al. [9] reported an SCLC 
patient with anti-Hu antibody who experienced a recur-
rence of SCLC with a secondary PNS. However, in con-
trast to our cases, those patients had a secondary PNS 
different from the first one [8, 9]. Anti-Hu antibody is 
related to some types of PNS, such as sensory neuropa-
thy, cerebellar ataxia and limbic encephalitis [10]. On 
the other hand, P/Q-type VGCC antibody was relatively 
specific to LEMS. The antibody was detected in 85–90% 
Fig. 3 Radiological findings and electromyography in the SCLC patient with LEMS at the age of 85 years. a Chest contrast CT revealed mediasti-
nal and pulmonary hilar lymphadenopathy (arrow) on March 10, 2015. B, 2-deoxy-2-[18F]fluoro-d-glucose (FDG) positron emission tomography 
(PET)-CT showed FDG accumulation in the mediastinal and pulmonary hilar lymph nodes (arrow) on March 24, 2015. c Electromyography following 
stimulation at 20 Hz showed waxing on April 9, 2015
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of patients with LEMS [11] and 10 of 12 SCLC patients 
with the P/Q-type VGCC antibody had LEMS [1]. This 
might be owing to the difference between our case and 
the cases reported in literature. It is unclear how the type 
of PNS was determined, although the same antibody was 
detected. Further study is needed to understand the etiol-
ogy of PNS.
Conclusions
Recurrence of both SCLC and LEMS after a DFS period 
of more than 10 years is rare. However, careful screening 
for cancer recurrence is needed if the patient has a recur-
rence or a secondary PNS.
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Fig. 4 Cytological findings in the SCLC patient with LEMS at the age of 85 years. Specimens were obtained by cervical lymph node needle aspira-
tion biopsy on March 3, 2015. Paraffin-embedded sections were stained with antibody using the polymer method and signal was developed with 
DAB. Sections were counterstained with hematoxylin. Positive staining for markers in cytoplasm and on cell membrane was indicated in brown.  
a Cytological examination revealed small cell carcinoma. b CD56 was diffusely and strongly positive on cell membrane. c Chromogranin A was 
focally and moderately expressed in cytoplasm. d Synaptophysin was not expressed in cytoplasm
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